| scholarly article | Q13442814 |
| P356 | DOI | 10.1161/01.CIR.96.1.61 |
| P698 | PubMed publication ID | 9236418 |
| P2093 | author name string | Klein W | |
| Ludwig K | |||
| Buchwald A | |||
| Turpie AG | |||
| van der Meer J | |||
| Sanz G | |||
| Monrad S | |||
| Hillis SE | |||
| Olaisson E | |||
| Undeland S | |||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | heparin | Q190016 |
| placebo | Q269829 | ||
| coronary artery disease | Q844935 | ||
| P304 | page(s) | 61-68 | |
| P577 | publication date | 1997-07-01 | |
| P1433 | published in | Circulation | Q578091 |
| P1476 | title | Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC) | |
| P478 | volume | 96 |
| Q35590045 | A comparative study of dalteparin and unfractionated heparin in patients with unstable angina pectoris |
| Q28186283 | A critical review of clinical trials for low-molecular-weight heparin therapy in unstable coronary artery disease |
| Q77535802 | A perspective on the regulation of the evaluation of new antithrombotic drugs |
| Q28269998 | A randomized controlled clinical trial to evaluate the efficacy, safety, cost-effectiveness and effect on PAI-1 levels of the three low-molecular-weight heparins--enoxaparin, nadroparin and dalteparin. The ESCAPe-END study |
| Q59356505 | ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the M |
| Q73245550 | Acute Myocardial Infarction: Antithrombotic Therapy |
| Q43564466 | Acute coronary care and beyond: the expanding role of low-molecular-weight heparin |
| Q34531478 | Acute ischemic syndromes. Adjunctive therapy |
| Q77766241 | Admission risk assessment by cardiac troponin T in unstable coronary artery disease: additional prognostic information from continuous ST segment monitoring. TRIM study group. Thrombin Inhibition in Myocardial Ischemia |
| Q33655204 | Advances in the medical management of acute coronary syndromes |
| Q33671960 | Aggressive versus conservative therapy in unstable angina |
| Q44961015 | An economic evaluation of the costs and benefits of heparin rationalisation in a hospital pharmacy |
| Q44618349 | Angiotensin Subtype 1 Receptor (AT1) Blockade Improves Vasorelaxation in Heart Failure by Up-Regulation of Endothelial Nitric-Oxide Synthase via Activation of the AT2Receptor |
| Q33671937 | Anticoagulant therapy in unstable angina. |
| Q33330179 | Anticoagulants in acute coronary syndromes |
| Q30402038 | Anticoagulation in the management of non-ST-segment elevation acute coronary syndrome |
| Q33671940 | Antiplatelet therapy for treatment of acute coronary syndromes |
| Q33951286 | Antithrombins and the importance of good control |
| Q28186369 | Antithrombotic therapy in acute coronary syndromes: key notes from ESSENCE and TIMI 11B |
| Q33635831 | Antithrombotic therapy of unstable angina and non-Q-wave myocardial infarction |
| Q37420492 | Application of basic and composite thrombelastography parameters in monitoring of the antithrombotic effect of the low molecular weight heparin dalteparin: an in vivo study |
| Q24806932 | Arterial indications for the low molecular weight heparins |
| Q33989688 | Assessment of low-molecular-weight heparin trials in cardiology |
| Q37077188 | Bioequivalence study of two subcutaneous formulations of dalteparin: randomized, single-dose, two-sequence, two-period, cross-over study in healthy volunteers |
| Q73507346 | Calming the plaque to delay intervention for 24 hours in acute coronary syndromes |
| Q33841025 | Can we differentiate the low-molecular-weight heparins? |
| Q77298805 | Clinical potential of antithrombotic drugs in coronary syndromes |
| Q33803411 | Clinical trials of low-molecular-weight heparins in cardiology |
| Q47226610 | Clinical trials of unfractionated heparin and low-molecular-weight heparin in addition to aspirin for the treatment of unstable angina pectoris: do the results apply to all patients? |
| Q47226633 | Comparing the antithrombotic efficacy of a humanized anti-factor IX(a) monoclonal antibody (SB 249417) to the low molecular weight heparin enoxaparin in a rat model of arterial thrombosis |
| Q44397609 | Comparison of effects on markers of blood cell activation of enoxaparin, dalteparin, and unfractionated heparin in patients with unstable angina pectoris or non-ST-segment elevation acute myocardial infarction (the ARMADA study). |
| Q28194967 | Cost effectiveness of extended treatment with low molecular weight heparin (dalteparin) in unstable coronary artery disease: results from the FRISC II trial |
| Q73419046 | Cost-effectiveness analysis of enoxaparin versus unfractionated heparin for acute coronary syndromes. A Canadian hospital perspective |
| Q44492670 | Cost-effectiveness analysis of enoxaparin versus unfractionated heparin in patients with acute coronary syndrome in Poland: modelling study from the hospital perspective. |
| Q28165924 | Costs and cost effectiveness of low molecular weight heparins and platelet glycoprotein IIb/IIIa inhibitors: in the management of acute coronary syndromes |
| Q35012976 | Critical appraisal of transesophageal echocardiography in cardioversion of atrial fibrillation |
| Q40067699 | Current dosing of low-molecular-weight heparins does not reflect licensed product labels: an international survey |
| Q83014706 | Dalteparin-associated catastrophic retroperitoneal hematoma successfully treated with recombinant factor VIIa |
| Q33993713 | Dalteparin: an update of its pharmacological properties and clinical efficacy in the prophylaxis and treatment of thromboembolic disease |
| Q34995139 | Defining the scope of evidence-based practice for low-molecular-weight heparin therapy in high-risk patients with unstable angina and non-ST-elevation myocardial infarction. |
| Q28186364 | Developing a novel antithrombotic in the academic environment |
| Q32049893 | Dosing and monitoring of low-molecular-weight heparins in special populations |
| Q35152090 | Dosing considerations and monitoring of low molecular weight heparins and glycoprotein IIb/IIIa antagonists in patients with renal insufficiency |
| Q34503038 | Dosing practice of low molecular weight heparins and its efficacy and safety in cardiovascular inpatients: a retrospective study in a Chinese teaching hospital |
| Q33984105 | Early-invasive or early-conservative management of patients with unstable angina or non-Q-wave myocardial infarction |
| Q73018305 | Economic evaluation of enoxaparin sodium versus heparin in unstable angina. A French sub-study of the ESSENCE trial |
| Q47731110 | Effect of dalteparin on atherosclerotic lesion formation in apolipoprotein E-deficient mice |
| Q47242410 | Effect of low molecular weight heparin (fragmin) on bleeding after cardiac surgery |
| Q28195417 | Effects of PEG-hirudin in clotting parameters and platelet function and its interaction with aspirin in healthy volunteers |
| Q28176380 | Effects of long-term, moderate-intensity oral anticoagulation in addition to aspirin in unstable angina. The Organization to Assess Strategies for Ischemic Syndromes (OASIS) Investigators |
| Q42168457 | Effects of preoperative enoxaparin versus unfractionated heparin on bleeding indices in patients undergoing coronary artery bypass grafting |
| Q74012811 | Effects of various anticoagulant treatments on von Willebrand factor release in unstable angina |
| Q37949587 | Emerging therapies for acute coronary syndromes |
| Q28192886 | Enoxaparin in unstable angina/non-ST-segment elevation myocardial infarction: treatment benefits in prespecified subgroups |
| Q28213718 | Enoxaparin injection for the treatment of high-risk patients with non-ST elevation acute coronary syndrome |
| Q44532762 | Enoxaparin versus tinzaparin in non-ST-segment elevation acute coronary syndromes: the EVET trial |
| Q77120999 | Enoxaparin. A review of its clinical potential in the management of coronary artery disease |
| Q34698784 | Enoxaparin: an update of its clinical use in the management of acute coronary syndromes. |
| Q46642672 | Evidence-based emergency medicine at the 'coal face'. |
| Q28210674 | Evidence-based medical therapy of patients with acute coronary syndromes |
| Q37070772 | Evolution of anticoagulant and antiplatelet therapy: benefits and risks of contemporary pharmacologic agents and their implications for myonecrosis and bleeding in percutaneous coronary intervention. |
| Q36035257 | Evolving role of low-molecular-weight heparins in ST-elevation myocardial infarction |
| Q33881653 | Formulary management of low molecular weight heparins |
| Q73695237 | Fragmin in unstable angina pectoris or in non-Q-wave acute myocardial infarction (the FRIC study). Fragmin in Unstable Coronary Artery Disease |
| Q28184207 | General pharmacologic treatment of acute myocardial infarction |
| Q33337743 | Glycoprotein IIb/IIIa antagonists and low-molecular weight heparin in acute coronary syndromes |
| Q34130613 | Guideline for the management of patients with acute coronary syndromes without persistent ECG ST segment elevation. British Cardiac Society Guidelines and Medical Practice Committee and Royal College of Physicians Clinical Effectiveness and Evaluati |
| Q28239975 | Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology |
| Q33846408 | Guidelines for the diagnosis and management of unstable angina and non-Q-wave myocardial infarction: proposed revisions. International Cardiology Forum |
| Q42711606 | Heparin should be administered to every patient admitted to the hospital with possible unstable angina |
| Q73906883 | Heparins in management of acute coronary syndromes without ST-segment elevation |
| Q47448786 | Hospital guidelines for use of low-molecular-weight heparins |
| Q47228689 | Impact of enoxaparin low molecular weight heparin in patients with Q-wave myocardial infarction |
| Q33743233 | Implications of the Organization to Assess Strategies for Ischemic Syndromes-2 (OASIS-2) study and the results in the context of other trials. |
| Q73425805 | In-hospital evolution and current prognosis of unstable angina |
| Q40829792 | Influences of sex and smoking habits on anticoagulant activity in low-molecular-weight heparin treatment of unstable coronary artery disease |
| Q73459961 | Introduction: Expanding the horizons in unstable coronary artery disease |
| Q36532549 | Investigation of the effect of Interleukin-1 receptor antagonist (IL-1ra) on markers of inflammation in non-ST elevation acute coronary syndromes (The MRC-ILA-HEART Study). |
| Q35691998 | Is the use of unfractionated heparin in acute coronary syndrome outmoded? |
| Q34051300 | Ischemic complications after percutaneous transluminal coronary angioplasty |
| Q33360869 | Lepirudin: a bivalent direct thrombin inhibitor for anticoagulation therapy |
| Q74006855 | Limitation of vWf meta-analysis in LMWH comparison |
| Q30305915 | Long-term effects of diltiazem and verapamil on mortality and cardiac events in non-Q-wave acute myocardial infarction without pulmonary congestion: post hoc subset analysis of the multicenter diltiazem postinfarction trial and the second danish ver |
| Q47302342 | Long-term low-molecular-weight heparin (Fragmin) and/or early revascularization during instability in coronary artery disease (the FRISC II Study). |
| Q33841036 | Long-term management--the way forward? |
| Q47269645 | Low molecular weight heparin (dalteparin) as adjuvant treatment of thrombolysis in acute myocardial infarction--a pilot study: biochemical markers in acute coronary syndromes (BIOMACS II). |
| Q35578899 | Low molecular weight heparin (enoxaparin) in the management of unstable angina: the ESSENCE study. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q wave Coronary Events. |
| Q28192889 | Low molecular weight heparin and unfractionated heparin in the early pharmacologic management of acute coronary syndromes: a meta-analysis of randomized clinical trials |
| Q41875513 | Low molecular weight heparin as an adjunct to thrombolysis for acute myocardial infarction: the FATIMA study. Fraxiparin Anticoagulant Therapy in Myocardial Infarction Study Amsterdam (FATIMA) Study Group. |
| Q33936337 | Low molecular weight heparin in acute coronary syndrome: evidence for superior or equivalent efficacy compared with unfractionated heparin? |
| Q34027303 | Low molecular weight heparin in acute coronary syndromes |
| Q43018603 | Low molecular weight heparins (enoxaparin) in the management of unstable angina: the TIMI studies. Thrombolysis in Myocardial Infarction. |
| Q34027403 | Low molecular weight heparins and coronary artery disease |
| Q34158943 | Low molecular weight heparins for arterial thrombosis |
| Q33503951 | Low molecular weight heparins in acute ischaemic syndromes |
| Q33663290 | Low molecular weight heparins in the cardiac catheterization laboratory |
| Q24250287 | Low molecular weight heparins versus unfractionated heparin for acute coronary syndromes |
| Q57243775 | Low-Molecular-Weight Heparin in Acute Coronary Syndromes |
| Q47246171 | Low-molecular-weight heparin as optimal solution to therapeutic heparinization |
| Q34069662 | Low-molecular-weight heparin in patients with non-ST-segment elevation acute coronary syndrome: role in the emergency department |
| Q61055444 | Low-molecular-weight heparin in the prevention and treatment of thromboembolic disorders |
| Q33704601 | Low-molecular-weight heparin should replace unfractionated heparin in the management of acute coronary syndromes |
| Q77919968 | Low-molecular-weight heparins |
| Q33378783 | Low-molecular-weight heparins : mechanisms, trials, and role in contemporary interventional medicine |
| Q41707230 | Low-molecular-weight heparins for acute coronary syndromes |
| Q33803415 | Low-molecular-weight heparins for acute coronary syndromes: an emergency medicine perspective |
| Q36545687 | Low-molecular-weight heparins in conjunction with thrombolysis for ST-elevation acute myocardial infarction. A critical review of the literature |
| Q47281499 | Low-molecular-weight heparins in non-ST-segment elevation ischemia: the ESSENCE trial. Efficacy and Safety of Subcutaneous Enoxaparin versus intravenous unfractionated heparin, in non-Q-wave Coronary Events |
| Q37490581 | Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings |
| Q35096649 | Low-molecular-weight heparins: are they all the same? |
| Q33618610 | Low-molecular-weight heparins: pharmacoeconomic decision modeling based on meta-analysis data |
| Q47281516 | Low-molecular-weight heparins: pharmacologic profile and product differentiation |
| Q34430449 | Low-molecular-weight heparins: weeks or months instead of days of treatment |
| Q30305538 | Management of Acute Ischemic Coronary Syndromes: The Present and Future |
| Q33996007 | Management of coronary artery disease: therapeutic options in patients with diabetes |
| Q33671970 | Management of high-risk subsets in unstable angina |
| Q34081546 | Management of intermediate coronary syndrome: role of conservative treatment, glycoprotein IIb/IIIa receptor inhibitors, and direct intervention |
| Q24653318 | Management of patients with unstable angina / non-ST-elevation myocardial infarction: a critical review of the 2007 ACC /AHA guidelines |
| Q58375778 | Management of unstable coronary-artery disease |
| Q40858772 | Management strategies for a better outcome in unstable coronary artery disease |
| Q40797559 | Management strategies in unstable coronary artery disease--current problems and future directions. The UCAD Council |
| Q34084217 | Medical therapy of unstable angina and non-Q-wave myocardial infarction |
| Q47281487 | Monitoring of low-molecular-weight heparins in cardiovascular disease |
| Q33576224 | New advances in the management of acute coronary syndromes: 4. Low-molecular-weight heparins. |
| Q33723971 | New antithrombotic and antiplatelet treatment |
| Q78171063 | New antithrombotic treatment in unstable coronary syndrome--for whom? |
| Q41593809 | New frontiers in the management of unstable coronary artery disease |
| Q28184399 | New heparin dosing recommendations for patients with acute coronary syndromes |
| Q33655209 | New thrombolytics, anticoagulants, and platelet antagonists: the future of clinical practice |
| Q28194215 | New treatment guidelines for unstable angina/non-ST-segment elevation myocardial infartion |
| Q33781946 | New-generation anticoagulants: the low molecular weight heparins |
| Q33838920 | Newer antithrombotic strategies in the initial management of non-ST-segment elevation acute coronary syndromes |
| Q73236730 | Non-Q-Wave Myocardial Infarction |
| Q28196421 | Optimal medical management of angina |
| Q33699818 | Optimal treatment of patients with acute coronary syndromes and non-ST-elevation myocardial infarction |
| Q39428614 | Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trial. FRISC II Investigators. Fast Revascularisation during Instability in Coronary artery disease |
| Q35113923 | Outpatient Management of the Chronically Anticoagulated Patient for Elective Surgery |
| Q44144598 | Pathway of oral absorption of heparin with sodium N-[8-(2-hydroxybenzoyl)amino] caprylate |
| Q34056269 | Pharmacokinetics and pharmacodynamics of oral heparin solid dosage form in healthy human subjects |
| Q28195424 | Pharmacologic plaque passivation for the reduction of recurrent cardiac events in acute coronary syndromes |
| Q33685447 | Pharmacological and clinical differences between low-molecular-weight heparins: implications for prescribing practice and therapeutic interchange. |
| Q28193946 | Pharmacological treatment of elderly patients with acute coronary syndromes without persistent ST segment elevation |
| Q33340342 | Pharmacology of low molecular weight heparins |
| Q26862694 | Pharmacotherapy in the cardiac catheterization laboratory: evolution and recent developments |
| Q28191816 | Prospective comparison of hemorrhagic complications after treatment with enoxaparin versus unfractionated heparin for unstable angina pectoris or non-ST-segment elevation acute myocardial infarction |
| Q28196500 | Prothrombotic and antithrombotic pathways in acute coronary syndromes |
| Q47229682 | Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: one-year results of the ESSENCE Study. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q Wave Coronary Events |
| Q47281509 | Rationale for the management of coronary syndromes with low-molecular-weight heparins |
| Q43899357 | Rebound thrombin generation after heparin therapy in unstable angina. A randomized comparison between unfractionated and low-molecular-weight heparin |
| Q33802938 | Regular review: treatment possibilities for unstable angina |
| Q34445660 | Risk stratification in non-ST segment elevation acute coronary syndromes with special focus on recent guidelines. |
| Q35944733 | Role of low-molecular-weight heparin in invasive management of non-ST-elevation acute coronary syndromes |
| Q33904621 | Role of low-molecular-weight heparins in the management of patients with unstable angina pectoris and non-Q-wave acute myocardial infarction |
| Q47176029 | Safety and effectiveness of combined low molecular weight heparin and glycoprotein IIb/IIIa inhibitors |
| Q33365516 | Safety profile of different low-molecular weight heparins used at therapeutic dose |
| Q77761609 | Session highlights from the European Society of Cardiology XXth Annual Congress: August 22 to 26, 1998 |
| Q36324876 | Some issues with composite endpoints in clinical trials |
| Q78769523 | TACT method for non-inferiority testing in active controlled trials |
| Q74653973 | TIMI 11B. Enoxaparin versus unfractionated heparin for unstable angina or non-Q-wave myocardial infarction: a double-blind, placebo-controlled, parallel-group, multicenter trial. Rationale, study design, and methods. Thrombolysis in Myocardial Infar |
| Q28165987 | The Role of Enoxaparin in Interventional Management of Patients with Acute Coronary Syndromes |
| Q44307922 | The activated clotting time can be used to monitor the low molecular weight heparin dalteparin after intravenous administration |
| Q41593833 | The continuing debate: conservative or interventional therapy for unstable coronary artery disease |
| Q42015226 | The end of the heparin pump? Dosage regimens for low molecular weight heparins differ |
| Q44541858 | The impact on coagulation of an intravenous loading dose in addition to a subcutaneous regimen of low-molecular-weight heparin in the initial treatment of acute coronary syndromes. |
| Q42921622 | The primacy of clinical effectiveness for cost effectiveness analysis |
| Q33347022 | The role of low-molecular-weight heparin in the management of acute coronary syndromes |
| Q34071460 | The role of low-molecular-weight heparins in arterial diseases: optimizing antithrombotic therapy |
| Q34282896 | The role of low-molecular-weight heparins in the management of unstable angina and non-ST-segment elevation myocardial infarction |
| Q33357627 | The use of Low Molecular Weight Heparin to Predict Clinical Outcome in Patients with Unstable Angina That Had Undergone Percutaneous Coronary Intervention |
| Q34648639 | Therapeutic equivalency of low-molecular-weight heparins |
| Q34158934 | Therapy of unstable angina with the low molecular weight heparins |
| Q47256701 | Thrombotic reactant markers in non-ST segment elevation acute coronary syndromes treated with either enoxaparin (low molecular weight heparin) or unfractionated heparin |
| Q38000240 | Treatment dosing of low-molecular-weight heparins and the dose cap dilemma: considerations for patients in Canada |
| Q72999601 | Treatment of unstable angina: role of antithrombotic therapy |
| Q47236623 | Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis |
| Q73308501 | Unfractionated heparin is the heparin of choice in the management of patients with acute coronary syndromes |
| Q34674179 | Unfractionated versus fractionated heparin for percutaneous coronary intervention |
| Q40737172 | Unstable Angina |
| Q40666251 | Unstable Angina and Non-ST-Segment Elevation Myocardial Infarction |
| Q33345502 | Use of a combination of enoxaparin or unfractionated heparin and abciximab during percutaneous coronary interventions: a randomized pilot study |
| Q40789233 | Usefulness of hospital admission risk stratification for predicting nonfatal acute myocardial infarction or death six months later in unstable angina pectoris. RESCATE Study Group. Resources Used in Acute Coronary Syndromes and Delays in Treatment. |
| Q44311325 | Utilisation and safety of low molecular weight heparins: prospective observational study in medical inpatients |
| Q46494898 | Which heparin and how much? |
| Q73353163 | [Low molecular weight heparin in the treatment of acute coronary syndromes without ST-segment elevation: unstable angina and non-Q-wave myocardial infarction] |
| Q77616333 | [Therapeutic management of acute ischemic heart disease without ST increase] |
| Q73038813 | [Therapy of acute coronary syndrome. Aspirin, heparin, low-molecular-weight heparin, hirudin and GP-IIb/IIIa blockers] |
| Q73857152 | [Thromboembolism prevention in acute myocardial infarction] |
| Q26829973 | 2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Associat |
Search more.